Table 2. JEV peptides eliciting T cell responses identified in this study
SubjectPeptideSubsetJEV proteinAmino acid locationTypeHLA restrictionHLA class IHLA class II
ABCDR
JE082/2GKNRAINMLKRGLPRVFCD4C9–25JE11:01, 33:0113:01, 44:02DR12, DR14, DR52
VFPLVGVKRVVMSLLDGRCD4C24–41
JE093/2MLKRGLPRVFPLVGVKRVVMSLLDGRCD4C16–41JE24:02, 24:0213:01, 27:02DR15, DR51
JE043/2SLVNKKEAWLDSTKATRYCD8M230–247JE01:01, 11:0152:01, 57:01DR3, DR15, DR52, DR51
WIIRNPGYAFLAAVLGWMCD4M254–271
JE101/2RYLMKTENWIIRNPGYAFCD4M246–263JE30:01, 33:0113:01, 44:02DR7, DR53
JE017/2AKFSCTSKAIGRTIQCD4E411–425JE03:01, 11:0207:02, 35:01DR4, DR11, DR52, DR53
KQSVVALGSQEGGLHQALCD4E543–560
CRLKMDKLALKGTTYGMCTEKFSFCD4E581–604
HGTVVIELSYSGSDGPCKCD4E613–630
LGKAFSTTLKGAQRLAALCD4E697–714
WDFGSIGGVFNSIGKAVHQVFGGAFCD4E719–735
GVLVFLATNVHADTGCAICD4E783–801
H021/1PWTSPSSTAWRNRELLMCD4E518–534H02:01, 11:0107:02, 52:01DR15, DR51
JE003/2KYLPETPRSLAKIVHKCD4 + CD8NS1827–842JE03:01, 33:0115:01, 37:01DR10, DR15, DR51
AVHSDLSYWIESRYNDTWKLERAVFCD4NS1987–1011
WIESRYNDTWKLERAVFGEVKSCTWCD4NS1995–1019
JE001/2EAWVDRYKYLPETPRSLAKIVHKCD4NS1820–842JE11:01, 31:0135:01, 52:21DR4, DR15, DR53, DR51
TYALNTFTNIAVQLVRLMCD8NS53136–3153
H014/3TAVLAPTRVVAAEMAEALCD8NS31723–1740H03:01, 30:0107:02, 13:0106:02, 07:01
H001/1ALRGLPVRYCD8NS31739–1747H11:01, 32:0115:01, 55:0101:02, 04:01
H001/4DVMCHATLCD8NS31763–1770DB*08:0101:01, 03:0108:01, 44:0205:01, 07:01DR8, DR17, DR52
H019/1NLFVMDEAHFTDPASICD8NS31784–1799H02:0138:01, 40:0607:01, 15:02
EAHFTDPASIAARGYICD8NS31790–1805
H013/3NLFVMDEAHFTDPASICD4NS31784–1799H02:01, 24:0235:03, 40:0602:21, 15:02
EAHFTDPASIAARGYICD4 + CD8NS31790–1805
GEAAAIFMTCD8NS31812–1820
JE098/2ELGEAAAIFMTATPPCD8NS31810–1824JE02:0135:01, 40:0604:01, 07:01
H005/1GCGRGGWSYYAATLKKVCD8NS52608–2624H02:01, 30:0113:01, 38:0106:02, 12:02
RGYTKGGAGHEEPMLMCD8NS52628–2643
H010/4LMQSYGWNLCD8NS52642–2650D01:01, 02:0108:01, 35:0104:01, 07:01
LVSLKSGVDVFYKPSCD8NS52650–2664
YMPKVIEKMEVCD8NS52714–2724
NMTSQVLLGRMDRTVWRCD8NS52761–2777
HPYRTWTYCD8NS52827–2834B*35:01
TPFGQQRVFCD4 + CD8NS52873–2884
JE080/2KLNAMSREEFFKYRREAIIEVDRCD4NS52542–2564JE02:01, 33:0115:05, 44:02DR7, DR53
TWHKDPEHPYRTWTYHGSYEVKCD4NS52820–2841
H007/2TMAMTDTTPFGQQRVFKCD4 + CD8NS52869–2885H01:01, 68:0157:01DR53, DR7
H011/3TMAMTDTTPFGQQRVFKCD8NS52869–2885H02:01, 68:0137:01, 51:0106:02, 15:02
H007/3TMAMTDTTPFGQQRVFKCD4 + CD8NS52869–2885H11:01, 68:0107:02, 52:0207:01, 12:02
CTKEEFIKKVNSNAALCD8NS52923–2938
DIAGKQGGKMYADDTAGWCD4NS53050–3067
H002/3IWFMWLGARYCD8NS53003–3012H01:01, 29:0107:05, 57:0106:02, 15:04
RYLEFEALGFLCD4NS53011–3021
JE054/2AISGDDCVVKPLDDRFATALHFLCD8NS53191–3213JE11:01, 24:0215:25, 51:0107:01, 16:01
JE074/2CVVKPLDDRFATALHFLCD8NS53197–3213JE
H008/4MTTEDMLQVWCD4 + CD8NS53336–3345HB*58:0101:01, 33:0358:01, 15:1707:01, 03:04DR13, DR15, DR51, DR52
CSAVPVDWCD8NS53312–3319B*58:01
JE446/2GEWMTTEDMLQVWNRVWICD4NS53333–3350JE01:01, 33:0152:01, 58:01DR14, DR15, DR52, DR51
MLQVWNRVWIEENEWMMCD8NS53341–3357

JE, recovered JE patient; H, healthy JEV-exposed donor; D, dengue exposed. In total, 57 responses to 40 peptides (or adjacent pairs of peptides) were identified.